Published in Hepatitis Weekly, September 9th, 2002
Assuming adequate financial resources, the company intends to initiate clinical trials this fall.
"Allowance of our IND for liver cell therapy by the FDA is a tribute to the quality of the work performed by Incara's development team. Developing a pharmaceutical grade cell therapy product is a difficult task that applies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly